RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation
NASDAQ:RIGL • US7665597024
Current stock price
25.81 USD
-0.56 (-2.12%)
At close:
25.81 USD
0 (0%)
After Hours:
This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RIGL Profitability Analysis
1.1 Basic Checks
- In the past year RIGL was profitable.
- RIGL had a positive operating cash flow in the past year.
- In multiple years RIGL reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- RIGL has a better Return On Assets (71.46%) than 99.61% of its industry peers.
- RIGL has a better Return On Equity (93.75%) than 99.61% of its industry peers.
- RIGL's Return On Invested Capital of 23.92% is amongst the best of the industry. RIGL outperforms 97.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROIC | 23.92% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 124.72%, RIGL belongs to the best of the industry, outperforming 98.84% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 42.63%, RIGL belongs to the top of the industry, outperforming 98.65% of the companies in the same industry.
- The Gross Margin of RIGL (93.33%) is better than 93.83% of its industry peers.
- In the last couple of years the Gross Margin of RIGL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
2. RIGL Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
- RIGL has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
- RIGL has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.31, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of RIGL (1.31) is better than 63.58% of its industry peers.
- The Debt to FCF ratio of RIGL is 0.69, which is an excellent value as it means it would take RIGL, only 0.69 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.69, RIGL belongs to the top of the industry, outperforming 94.80% of the companies in the same industry.
- A Debt/Equity ratio of 0.06 indicates that RIGL is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.06, RIGL is in line with its industry, outperforming 41.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 1.31 |
ROIC/WACC2.45
WACC9.77%
2.3 Liquidity
- RIGL has a Current Ratio of 2.42. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.42, RIGL is doing worse than 71.48% of the companies in the same industry.
- A Quick Ratio of 2.30 indicates that RIGL has no problem at all paying its short term obligations.
- RIGL's Quick ratio of 2.30 is on the low side compared to the rest of the industry. RIGL is outperformed by 70.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 |
3. RIGL Growth Analysis
3.1 Past
- RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 593.62%, which is quite impressive.
- RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.15%.
- The Revenue has been growing by 22.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
3.2 Future
- Based on estimates for the next years, RIGL will show a decrease in Earnings Per Share. The EPS will decrease by -2.44% on average per year.
- The Revenue is expected to grow by 6.25% on average over the next years.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. RIGL Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 3.96, the valuation of RIGL can be described as very cheap.
- RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.04% of the companies in the same industry.
- RIGL is valuated cheaply when we compare the Price/Earnings ratio to 24.88, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 6.23 indicates a rather cheap valuation of RIGL.
- RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.65% of the companies in the same industry.
- RIGL is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.96 | ||
| Fwd PE | 6.23 |
4.2 Price Multiples
- RIGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.04% of the companies in the same industry.
- 98.84% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.3 | ||
| EV/EBITDA | 2.11 |
4.3 Compensation for Growth
- RIGL has a very decent profitability rating, which may justify a higher PE ratio.
- RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
5. RIGL Dividend Analysis
5.1 Amount
- RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RIGL Fundamentals: All Metrics, Ratios and Statistics
25.81
-0.56 (-2.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-04 2026-05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap476.71M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (102.32%)
Short Float %21.33%
Short Ratio9.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)9.35%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)7.12%
EPS NY rev (3m)-5.83%
Revenue NQ rev (1m)7.25%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)1.73%
Revenue NY rev (3m)-2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.96 | ||
| Fwd PE | 6.23 | ||
| P/S | 1.62 | ||
| P/FCF | 6.3 | ||
| P/OCF | 6.3 | ||
| P/B | 1.22 | ||
| P/tB | 1.3 | ||
| EV/EBITDA | 2.11 |
EPS(TTM)6.52
EY25.26%
EPS(NY)4.14
Fwd EY16.05%
FCF(TTM)4.1
FCFY15.87%
OCF(TTM)4.1
OCFY15.87%
SpS15.93
BVpS21.2
TBVpS19.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROCE | 30.28% | ||
| ROIC | 23.92% | ||
| ROICexc | 38.21% | ||
| ROICexgc | 42.24% | ||
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% | ||
| FCFM | 25.71% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | 19.09 | ||
| Cash Conversion | 59.16% | ||
| Profit Quality | 20.61% | ||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 1.31 |
F-Score6
WACC9.77%
ROIC/WACC2.45
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.59%
EBIT Next 3Y32.03%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.